FDA approves generic feline parasiticide
Vetoquinol USA received a regulatory go-ahead for Imoxi Topical Solution for Cats.
The U.S. Food and Drug Administration has approved Vetoquinol USA’s Imoxi Topical Solution for Cats, a generic equivalent of Bayer’s Advantage Multi antiparasitic.
The prescription drug’s approval came five months after the FDA authorized Imoxi Topical Solution for Dogs, which contains the same active ingredients.
Administered monthly, the feline version will be sold in three dosages based on a cat’s weight: 2 to 5 pounds, 5.1 to 9 pounds and 9.1 pounds or more.
Bayer Animal Health earned FDA approval of Advantage Multi for Cats (imidacloprid and moxidectin) in 2007.
Did you know a subscription to Today’s Veterinary Business is free to qualified veterinary professionals? All you have to do is sign up here (and renew each year). You also can sign up to receive the Today’s Veterinary Business weekly e-newsletter.